We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Subsidiary Formed to Market H Pylori Test

By Labmedica staff writers
Posted on 31 Mar 2005
A new subsidiary is being established by Orexo AB (Uppsala, Sweden) to commercialize the company's breath test for Helicobactor pylori.

The test is based on Orexo's patented technology for fast-dissolving tablets. More...
These tablets offer greater reliability, lower dose, shorter test time, and lower cost. The company has signed distribution and marketing agreements for the test, called Diabact UBT, with companies in Finland, Hong Kong, Ireland, the United Kingdom, and Sweden.

Orexo points out that by diagnosing H pylori infection and treating it with antibiotics, stomach ulcers can be effectively cured. In recent years, it has also been found that early treatment of H pylori infection can reduce the risk of developing certain forms of stomach cancer. Diabact UBT is the company's first commercialized product.

"Diabact UBT has significant market potential. To successfully capitalize on this potential, we are forming a subsidiary with the objective to create a strong position for the test in existing and new markets,” said Zsolt Lavotha, president and CEO of Orexo. "This subsidiary shall be provided with autonomy to actively in-license products and/or enhance its operation based on strategic transactions.”




Related Links:
Orexo AB

New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.